Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 4/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.44 |
| ▸ | BRAF | P15056 | 11/20 | 0.43 |
| ▸ | BRD4 | O60885 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6999608 | 0.91 | BRAF (0.41) | PTGS2PTGS1BRAFBRD4 | |
| SCHEMBL6998598 | 0.91 | PTGS2 (0.44) | PTGS2PTGS1BRAFBRD4 | |
| SCHEMBL7000963 | 0.90 | BRAF (0.44) | PTGS2PTGS1BRAFBRD4 | |
| SCHEMBL6994072 | 0.90 | BRAF (0.42) | PTGS2PTGS1BRAFBRD4 | |
| SCHEMBL6999336 | 0.89 | PTGS2 (0.50) | PTGS2PTGS1BRAFBRD4 | |
| SCHEMBL6997793 | 0.88 | PTGS2 (0.40) | PTGS2PTGS1BRAF | |
| SCHEMBL3234556 | 0.86 | PTGS2 (0.47) | PTGS2PTGS1BRAF | |
| SCHEMBL3223651 | 0.86 | PTGS2 (0.42) | PTGS2PTGS1BRAF | |
| SCHEMBL3228803 | 0.85 | PTGS2 (0.44) | PTGS2PTGS1BRAFBRD4 | |
| SCHEMBL6995210 | 0.85 | BRAF (0.39) | PTGS2PTGS1BRAF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2010-03-18 | — | — | US | claimed |
| WO-2005094815-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2005-10-13 | — | — | WO | claimed |
| US-20050222251-A1 | Dual inhibition of cyclooxygenase-2 and carbonic anhydrase | AMOREPACIFIC CORPORATION | 2005-10-06 | — | — | US | claimed |
| EP-1109799-B1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORP (KR) | 2003-12-17 | — | — | EP | claimed |
| US-6492416-B1 | TREATING INFLAMMATION AND ASSOCIATED DISORDERS | PACIFIC CORPORATION (KR) | 2002-12-10 | — | — | US | claimed |
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | AMOREPACIFIC CORPORATION (KR) | 2010-03-18 | — | — | US | disclosed |
| US-20050222251-A1 | Dual inhibition of cyclooxygenase-2 and carbonic anhydrase | AMOREPACIFIC CORPORATION | 2005-10-06 | — | — | US | disclosed |
| EP-1109799-B1 | 4,5-DIARYL-3(2H)-FURANONE DERIVATIVES AS CYCLOOXYGENASE-2 INHIBITORS | PACIFIC CORP (KR) | 2003-12-17 | — | — | EP | disclosed |
| US-6492416-B1 | TREATING INFLAMMATION AND ASSOCIATED DISORDERS | PACIFIC CORPORATION (KR) | 2002-12-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050222251-A1 | Dual inhibition of cyclooxygenase-2 and carbonic anhydrase | PTGS2, CA2, PTGES2 | PTGS2 1/4885PTGS1 4/4885BRAF 2964/4885 |
| US-20100069483-A1 | DUAL INHIBITION OF CYCLOOXYGENASE-2 AND CARBONIC ANHYDRASE | PTGS2, CA2, PTGES2 | PTGS2 1/4885PTGS1 4/4885BRAF 2964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.